Nexstim logo

Nexstim Plc - exercise of warrants pursuant to the financing arrangement announced on 21 July 2016

26 April 2017

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or the "Company"), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, announces that it has received a warrant exercise notice pursuant to the financing arrangement announced on 21 July 2016. Bracknor subscribes for a total of 3,543,586 new shares with a subscription price of EUR 0.1411 per share in accordance with the terms and conditions of the warrants. The aggregate subscription price for the shares subscribed for with warrants amounts therefore to EUR 499,999.98. The new shares will be listed approximately on 3 May 2017. After the exercise of the warrants the total number of registered shares in the Company will be 81,130,333.

NEXSTIM PLC

Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by contacting:

Nexstim                                                                        +447715163942

Martin Jamieson, Chairman and CEO         martin.jamieson@nexstim.com

                                                                                                                                                                                                        

UB Securities Oy (Certified Adviser)                                             +358 (0)9 2538 0246

Citigate Dewe Rogerson                                                               +44 (0)207 2821066

Katja Stout                                                                          katja.stout@citigatedr.co.uk

About Nexstim Plc

Nexstim is a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim’s NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain.

Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked for the treatment of stroke, major depression and chronic neuropathic pain. The NBT® system is currently in a supplemental Phase III study, E-FIT trial, which will recruit 60 patients. The trial is expected to complete in Q1 2018 allowing Nexstim to file for FDA clearance in April 2018. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.

Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

Back to Press Releases